Krystal Biotech (KRYS) Net Equity Issued and Repurchased (2017 - 2023)

Krystal Biotech has disclosed Net Equity Issued and Repurchased across 7 years of filings, most recently posting $10000.0 for Q4 2023.

• In Q4 2023, Net Equity Issued and Repurchased rose 100.25% year-over-year to $10000.0; the TTM figure through Dec 2024 stood at -$112000.0 (down 100.07% YoY), while the FY2023 annual figure was $159.7 million, up 451.01% from the prior year.
• Net Equity Issued and Repurchased came in at $10000.0 for Q4 2023 at Krystal Biotech, up from -$122000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $202.1 million in Q4 2021 to a low of -$3.9 million in Q4 2022.
• Average Net Equity Issued and Repurchased over 5 years is $38.5 million, with a median of $1.1 million recorded in 2020.
• Year-over-year, Net Equity Issued and Repurchased jumped 2350375.0% in 2019 and slumped 105.75% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at $299000.0 in 2019, then surged by 157.53% to $770000.0 in 2020, then jumped by 26143.12% to $202.1 million in 2021, then slumped by 101.95% to -$3.9 million in 2022, then surged by 100.25% to $10000.0 in 2023.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $10000.0 in Q4 2023, -$122000.0 in Q3 2023, and $157.6 million in Q2 2023.